Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $12.7628, but opened at $13.8475. Santen Pharmaceutical shares last traded at $13.8475, with a volume of 204 shares.
Wall Street Analyst Weigh In
Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.
Get Our Latest Research Report on SNPHY
Santen Pharmaceutical Stock Performance
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
Further Reading
- Five stocks we like better than Santen Pharmaceutical
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
